Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in a trial to compare once-daily versus twice-daily dosing of CTP-543 in alopecia areata patients.
Alopecia areata is an autoimmune disease that causes partial or complete loss of hair on the scalp and body. CTP-543 is a deuterium-modified ruxolitinib, which inhibits Janus kinases 1 and 2. The candidate has received FDA fast track designation.
The trial will include 57 adult alopecia areata patients who will receive either 8 mg of CTP-543 twice-daily or 16 mg of CTP-543 once-daily for 24 weeks. The trial will measure the relative change in severity of alopecia tool, or SALT, score.
“This dose regimen trial helps us understand the safety and efficacy of CTP-543 when dosed once-daily and allows us to set our dosing strategy for future late-stage trials,” James Cassella, Concert’s chief development officer, said in a statement.
Concert expects to report topline data from this trial in the fourth quarter of 2019.
